Prostate cancer risk assessment: Choosing the sharpest tool in the shed

Cancer

Volumn 113, Issue 11, 2008, Pages 3062-3066

  Cooperberg, Matthew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; EDITORIAL; HUMAN; PARSIMONY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

FORECASTING; HUMANS; MALE; NOMOGRAMS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 56649083756     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23920     Document Type: Editorial

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435-448.
3. American Urological Association Prostate Cancer Clinical Guidelines Panel. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. Linthicum, Md: American Urological Association Education and Research, Inc.; 2007.
4. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165:1562-1568.
5. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer. 2008;113:3075-3099.
6. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
7. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938-1942.
8. Penson DF, Grossfeld GD, Li YP, Henning JM, Lubeck DP, Carroll PR. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the Cancer of the Prostate Strategic Urological Research Endeavor. J Urol. 2002;167:1653-1657; discussion1657-1658.
9. Graefen M, Karakiewicz PI, Cagiannos I, et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol. 2002;7:141-146.
10. Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002;20:951-956.
11. May M, Knoll N, Siegsmund M, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1296 patients. J Urol. 2007;178:1957-1962.
12. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.. Urology. 2008;72:396-400.
13. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002;20:3206-3212.
14. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
15. Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol. 2004;171(6 pt 1):2255-2259.
16. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data From CaPSURE). J Urol. 2003;170(6 pt 2):S21-S27.
17. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545.
18. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-2172.
19. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003;21:4568-4571.
20. Cooperberg MR, Broering JM, Carroll PR. The UCSF Cancer of the Prostate Risk Assessment score accurately predicts metastasis, prostate cancer mortality, and all-cause mortality [abstract]. J Urol. 2008;179(4S). Abstract 321.
21. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era [abstract]. J Urol. 2008;179(4S). Abstract 1889.
22. Duan JJ, Piccirillo JF, Vlahiotis A, Luly JR, Kibel AS. Preoperative nomogram for overall 10-year survival after radical prostatectomy or radiation therapy for prostate cancer [abstract]. J Urol. 2008;179(4S). Abstract 1437.